HER3 and LINC00052 interplay promotes tumor growth in breast cancer

Supplementary Materials
Supplementary Figure S1 : Genomic analysis and expression of LINC00052. (A) Chr15 (q25. 3) mapping of LINC00052 genomic location and its corresponding expected transcriptional unit. The expected pre-mRNA of 2940 bp is marked by the red arrow. Arrows show location of primers used for RT-PCR, qRT-PCR and PCR analysis (FW, RV, Fe-1-2, Re3, Fi/Ri, Fwex3, Rvex3, nucleotide sequences are reported in Supplementary Table S1 ). (B, C) Schematic of LINC00052 conservation across the mammals (B) and primates (C). Genome comparative analysis showed that LINC00052 3'-end is highly conserved among mammals and high homology was found in primate species-conserved tracks according to: http://deepbase.sysu.edu.cn/. (D) Western blot analysis of potential protein expression of LINC00052. cDNA of LINC00052-sense (S) and LINC00052-antisense (AS) were cloned in frame with FLAG-tag inserted before the predicted stop codon. Resulting constructs were transduced in MCF7, T47D, or 293FT cells. Of note, no trace of LINC00052 protein product was detected after immunoblotting with antibody against FLAG-tag. Recombinant PARK7 bearing FLAG-tag was used as positive control.
in breast cancer MCF7, T47D and SKBR-3 cells (grown in 10% FBS) treated with 100 nM of lapatinib or vehicle for 30 min followed by NRG-1-stimulation for 60 min. (D) LINC00052 levels analyzed by qRT-PCR in T47D breast cancer cells treated with HER3 (referred as A14 and U59) and HER2 (Trasz) blocking antibodies. T47D cells were grown in 10% fetal serum bovine to reach 85% confluence followed by 18 hrs serum-starvation. Subsequently, cells were pre-treated for 30 min with 10 µg/ml B14 or U59 (HER3 neutralizing monoclonal antibodies) or trastuzumab (HER2 blocking antibody), followed by 60 min stimulation with 100 ng/ml of NRG-1 (+) or untreated (-), as indicated. LINC00052 and HER3 RNA relative expression were analyzed by qRT-PCR and whole cell lysates were analyzed by Western blot with antibodies against pHER3 and ACTIN. Of note, blocking monoclonal antibodies against HER3 but not against HER2 inhibit LINC00052 RNA expression upon NRG-1-stimulation. (E) Evaluation of LINC00052 by qRT-PCR in MCF7 breast cancer cells treated with trastuzumab. Cells were grown in 10% fetal serum bovine to reach 85% confluence followed by 18 hrs serum-starvation. Subsequently, cells were pre-treated for 30 min with 10 µg/ml trastuzumab or IgG-isotype (control). In vivo HER3 antibody treatment of nude mice bearing MCF7 xenografts of cells stably expressing LINC00052-ectopic or control GFP constructs. Two cohorts of SCID mice with size-matched tumors (n = 6/group) received 10 μg/g per dose of HER3 blocking antibody or negative control-PBS. Treated mice received a series of doses (n = 9) through intraperitoneal (i.p.) administration twice weekly. Experimental end-point 6-week tumors mass (mg, milligram) are shown. Mean ± SD is shown. *p < 0.05, **p < 0.01.
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